Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, recently announced it has completed its acquisition of Ambry Genetics, a ...

Erik Phelps, the Executive Vice President and Chief Administrative and Legal Officer of Tempus AI , Inc. (NASDAQ:TEM), ...

Andrew Polovin, the Executive Vice President and General Counsel of Tempus AI , Inc. (NASDAQ:TEM), a company currently valued at $10.2 billion, recently executed a stock sale as part of a pre-arranged ...

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry Genetics.

Nancy Pelosi's newest bet saw the purchase of Tempus AI call options — now, a Wall Street analyst has given the stock a new ...

The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.

Tempus AI has delivered an 82% YTD return, outperforming the broader market and AI-themed stocks amidst market volatility.

We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at ...

The tech world may be steering in a new direction with the emergence of DeepSeek and the cheaper and more efficient models it ...